Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simcere Enters Into Agreement With Tianda
Simcere Pharmaceutical (Simcere) has entered into an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical (Tianda). The company said that the acquisition
Simcere Pharmaceutical (Simcere) has entered into an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical (Tianda). The company said that the acquisition
TNO and Seventh Wave Laboratories (Seventh Wave) have signed a letter of intent with regard to TNO’s in-vitro gastrointestinal models TIM. The letter of intent proposes a collaboration
ISTA Pharmaceuticals has presented additional results from Bepreve (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. Bepreve is a non-sedating, highly selective antagonist of the histamine (H1)
Clinipace has closed its acquisition of Worldwide Clinical Research, (WWCR) on October 26th, 2009. With the acquisition, Clinipace has changed its name to Clinipace Worldwide. Reportedly, with specific
Enzon Pharmaceuticals has entered into a definitive agreement to sell its specialty pharmaceutical business to the Sigma-Tau Group for $300m plus an additional amount of up to $27m
NexBio has presented new data entitled ‘DAS181 (Fludase), a Sialidase, Decreases Airway Resistance and Has Potent Anti-inflammatory Effects in Animal Models of Asthma’. DAS181 (Fludase) is an investigational
Ikano Therapeutics (ITI) has received Orphan Drug designation for midazolam in the acute treatment of certain forms of epileptic seizure. ITI has a nasally administered form of midazolam
D-Pharm has entered into a licensing, co-development and supply agreement with Wanbang Biopharmaceuticals, for commercialisation of DP-b99 in the People’s Republic of China. DP-b99 is a novel drug
Concert Pharmaceuticals has initiated a Phase 1b clinical study with CTP-518, investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of
The FDA has accepted ChemGenex Pharmaceuticals’ (ChemGenex) New Drug Application (NDA) for Omapro (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed